Japan Lifeline (7575) Q2 2026 earnings summary

Executive summary

• Achieved record-high H1 net sales of ¥29,285 million (+4.6% YoY), operating profit of ¥6,620 million (+5.7% YoY), and net profit of ¥4,774 million (+7.7% YoY), driven by strong core product performance, expansion in new therapeutic areas, and partial bad debt recovery.

• Growth was supported by increased AF case volume, robust EP/Ablation and Cardiovascular segments, and high growth in Neurovascular and GI, offsetting a slight decline in Cardiac Rhythm Management.

• Negative impacts included faster-than-expected PFA adoption, reimbursement price revisions, and competitive pressure in pacemakers.

Financial highlights

• Gross profit margin declined to 60.0% (down 60bps YoY) due to a shift toward lower-margin procured products; operating margin rose to 22.6% (up 20bps YoY); net margin reached 16.3% (up 50bps YoY).

• EPS increased to ¥68.08 (+10.0% YoY), aided by share buybacks and cancellations.

• Operating profit increase was driven by sales and cost factors (+¥593 million), offset by SG&A factors (-¥234 million).

• Q2 FY3/2026 also saw record-high quarterly sales and profits, with net profit up 18.0% YoY.

• Comprehensive income was ¥4,667 million (down 0.3% YoY).

Outlook and guidance

• H1 results are in line with full-year guidance, with 49–51% progress toward annual targets for sales, operating profit, and net profit.

• Full-year forecast for FY ending March 31, 2026: net sales ¥59,300 million (+4.8% YoY), operating profit ¥12,900 million (+4.7% YoY), net profit ¥9,350 million (+0.3% YoY), EPS ¥133.30.

• Medium-term plan targets revised upward: FY3/2028 net sales target raised to ¥70 billion, operating margin to remain at 20%+.

• Profits slightly above guidance due to higher-than-expected bad debt recovery.

• Growth expected from new product launches, global expansion, and entry into new therapeutic areas.